Buy Like Buffett
Watchlist

Flagship explainer

How AMNEAL PHARMACEUTICALS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$3.0B · 100%Cost of revenue$1.9B · 63%Gross profit$1.1B · 37%Operating income$394M · 13%Income before tax$139M · 5%Income tax$11.3M · 0%Net income$72.1M · 2%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$3.0B100%
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
Cost of revenue$1.9B63%
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
$1.1B37%
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
$394M13%
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
Income before tax$139M5%
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
Income tax$11.3M0%
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
$72.1M2%
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001723128-26-000011 · filed Feb 27, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full AMNEAL PHARMACEUTICALS, INC. analysis at Buy Like Buffett